• Biospecimen SolutionsPrecision Value & HealthCareers
    P_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGBP_ForMedicine_no_tag_RGB
    • Clinical
      Trial Services
        • Overview
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

        • Global Clinical Trial Support –
            • North & South America –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Europe –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • APAC –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

        • Clinical Trial Management –
            • Study Start-up & Feasibility –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Project Management –
            • Patient Recruitment –
            • Personalized Clinical Trial Operations –
            • Biometrics –
            • Medical & Safety Monitoring –
            • Clinical Data Management –
            • Medical Writing –
        • Clinical Development Strategy –
            • Clinical Development Planning –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Strategies –
            • Cell & Gene Therapy Strategies –
            • CDx Regulatory and Market Access –
        • Clinical Trial Design –
            • Basket & Umbrella Trials –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Biomarker Clinical Trials –
            • Master Protocol Trials –
            • Decentralized Clinical Trials
        • Biostatistics –
            • Statistical Consulting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Study Design –
            • Data Monitoring Committees –
            • CDISC Programming and Documentation –
            • eCTD Submissions –
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Training
            • Oncology Clinical TrialsImage

              Oncology Clinical Trials


              Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

              • Rare & Orphan DiseaseImage

                Rare & Orphan Disease


                With experience built on 150+ orphan disease projects covering 80+ rare diseases, we know how to anticipate logistical and regulatory obstacles and craft bold solutions that drive rare disease development programs.

    • Lab
      Services
        • Central Lab Services –
            • Clinical Specimen Kitting –
              • Oncology Clinical TrialsImage

                Oncology Clinical Trials


                Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

            • Sample Processing –
            • Global Specimen Logistics and Biostorage –
            • Biospecimen Data Services –
            • Precision Lab e-Portal –
            • Virtual Sample Inventory Management –
        • Specialty Lab Services Overview –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • EU Contract Research Organization –
        • Immune Monitoring –
            • Immune Monitoring by Flow Cytometry –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • Immune Cell Phenotyping by Epiontis ID –
            • Cytokine Profiling –
            • Gene Expression Profiling –
            • ELISpot and FluoroSpot –
            • Custom Assays –
        • Flow Cytometry –
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

        • Genomics –
            • NanoString Assays –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • ddPCR –
            • qPCR –
            • NGS –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
        • Tissue & Liquid Biopsy –
            • ApoStream – CTC and Rare Cell Isolation for Liquid Biopsy
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • CTC / cfDNA / Exosome Analysis –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry –
            • Fluorescence In Situ Hybridisation (FISH) / ISH
            • Pathology Services –
            • NanoString Assays
        • Bioanalytical Testing –
            • Immunogenicity Testing –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • PK Assays –
            • ADA Assays –
            • MesoScale Discovery (MSD) Assays –
            • Quanterix SIMOA –
            • ELISA
        • Cytokine Analysis –
            • ELISA –
              • Immune MonitoringImage

                Immune Monitoring


                Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

            • MesoScale Discovery (MSD) Assays
            • Luminex –
            • Quanterix SIMOA
        • Preclinical Target and Biomarker Validation –
            • Cell Based Assays –
            • Target Expression – XpressWay Profiles –
            • Tissue Cross-Reactivity –
            • Fluorescence In Situ Hybridisation (FISH) / ISH –
            • Multiplex Immunofluorescence –
            • Immunohistochemistry (IHC)
        • Biospecimens
            • Immune MonitoringImage

              Immune Monitoring


              Leverage sophisticated immune monitoring approaches, including flow cytometry, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

              • Tissue & Liquid BiopsyImage

                Tissue and Liquid Biopsy


                Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

    • Data
      Sciences
        • Overview
            • BiostatisticsImage

              Biostatistics


              Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

              • Computational BiologyImage

                Computational Biology


                Domain experts from our QuartzBio team utilize integrated and harmonized data and tailored AI solutions to drive preclinical and clinical development, including patient stratification, signature development, predictive modeling of drug response, and MOA characterization.

        • Biostatistics
        • Clinical Data Management
        • Biometrics
        • QuartzBio –
            • Biomarker Data Management –
              • BiostatisticsImage

                Biostatistics


                Seasoned biostatisticians and statistical programmers support every phase of your trial, from study design for small, rare disease trials to regulatory submissions, all backed by meticulous documentation.

            • Virtual Sample Inventory Management –
    • Diagnostics
      & CDx
        • IVD and CDx Regulatory Affairs Consulting –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • COVID-19 & Viral Panel Assays –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Biospecimens Solutions 
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

        • Diagnostic Market Access Services –
          • spevialty_labs_slice-300×54Image

            Specialty Lab Services


            Our comprehensive approach starts with a foundation of expertise in key biomaker discovery and analysis methods such as immune monitoring, genomics, and bioanalysis.

    • Therapeutic
      Areas
        • Overview
            • By Specialty Area
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Oncology and Immuno-Oncology
              • Oncology Clinical Trials
            • Rare & Orphan Disease
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • Cell & Gene Therapy
              • Cell Therapy
              • Gene Therapy
              • Cell and Gene Therapy Manufacturing
            • CNS & Neuroscience
              • Global-clinical-trial-support-2Image

                Global Clinical Trial Support


                Sample processing labs, clinical trial sites and offices in five continents provide the clinical reach and scale to manage complex global programs.

            • COVID-19
            • AutoImmune & Allergy
            • Pediatric
            • Companion Diagnostics
        • By Research Phase
        • Preclinical Development –
        • Early Phase Trials (I-IIa) –
        • Late Phase Trials (IIb-III) –
    • News &
      Insights
        • Blog –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Resources –
        • Thought Leadership –
        • News –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

        • Events –
            • iStock-945738094Image

              Blog


              Industry trends and best practices from Precision experts

              • shutterstock_1033743346Image

                Resources


                A searchable hub featuring the latest Precision case studies, white papers, capabilities brochures and more.

    • About
      Us
        • Our Passion –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

        • Meet Our People –
        • Careers
        • Regulatory Information –
            • Patient RecruitmentImage

              Our Passion


              What we do, why we do it and the principles that guide us every day.

              • meet-our-peopleImage

                Meet Our People


                We are devoted professionals with deep expertise in translational science, clinical trials and data sciences.

    • Contact
      Us
    • Home
    • Decentralized trial strategies and their impact in rare disease studies

    Decentralized trial strategies and their impact in rare disease studies

    by Esther Mahillo on March 14, 2022 — 7 minute read

    DCTs reduce burdens and barriers for rare disease patients

    There are more than 7,000 rare diseases, and they affect approximately 4% of the total world population.1,2 These include genetic and environmental diseases as well as infectious illnesses and rare cancers. Although some rare diseases tend to be less rare in certain regions or within specific demographics, all rare diseases pose sizable challenges to patients and those dedicated to providing quality care and breakthrough treatments to address the multitude of unmet needs.

    Decentralized clinical trials (DCTs) and the patient-centric options they provide are proving to be a valuable solution to some of the unique challenges presented by rare disease research. In the face of readjustments caused by COVID-19, decentralized strategies allow patients, family members, caregivers, medical practitioners, and sponsors to conduct trials that are flexible and tailored to best suit a patient’s situation. More than ever before, these strategies are enabling patients and care teams to overcome some of the burdens associated with rare disease trial participation.

    Receiving a rare disease diagnosis and building a community

    Despite a myriad of challenges as the patient and caregivers navigate the pathway to obtain a diagnosis, patients and their loved ones relentlessly pursue a correct diagnosis and then research treatment opportunities. This process is often complicated, arduous, expensive, painful, and discouraging. For many patients, obtaining a rare disease diagnosis answers a lot of questions, while also bringing up new ones, spurring the search for understanding and knowledge about the disease and treatment.

    During that search, patients and their loved ones are fortunate if they are able to find resources and networks that not only share information and experiences, but also give additional support and a sense of camaraderie. These groups form close-knit patient advocacy communities and are involved in keeping each other up-to-date on the latest news related to the rare disease. They also promote the community’s interests with regulators, legislators, drug developers, and other key influencers. Social media platforms and virtual video technology have increased the ease of staying in touch globally and diffusing pertinent information.

    Upcoming trials are a frequent topic of discussion. The openness in these communities allows patients and their families to discuss their feelings about advances in research and clinical studies which may be of interest. Patients and parents, consider the experiences of other individuals participating in trials, including the phase of the research, previous research in humans, potential risks, and potential clinical benefits. Thanks to these communities and networks, there is greater access to trusted sources who are willing to share their thoughts and opinions regarding the research opportunities – and if there are more suitable studies and treatment options available.

    Benefits of participating in clinical trials

    • Potential to gain a clinical benefit for current patients
    • Potential to gain clinical benefits for future patients
    • Building connections within the rare disease community
    • Access to cutting-edge treatments and high-quality care
    • Providing trials with a diverse study enrollment

    Challenges in participating in clinical trials

    • Travel burdens on patients, family members, and caregivers
    • Financial burdens on patients, family members, and caregivers
    • Logistical burdens on and disruptions in everyday life
    • Specialized care required to travel to the clinic site (often far away)
    • Potential adverse side effects and invasive procedures
    Rare disease symptoms as barriers to DCT participation

    Patients, families, and caregivers weigh a variety of other factors when contemplating the benefits and drawbacks of participating in a trial. These factors often relate to the burdens and barriers of participation, and how enrolling affects current and long-term daily life.

    Rare diseases can display a wide spectrum of phenotypes, for example, from severe to attenuated, and therefore affect a patient’s neurological, behavioral, and skeletal systems, among others. Symptoms can vary tremendously among patients even with the same rare disease diagnosis, and severe symptoms directly correlate to how greatly a disease impacts the patient’s life. Some of these symptoms may cause it to be extremely difficult for patients to participate in less flexible trials; for example, traveling to a clinical site may require specialized planning for caregivers and transportation equipment like dedicated nurses and oxygen tanks to attend a study visit.

    Sponsors and others in the clinical trial space need to understand these decision factors and burdens as thoroughly as possible in order to take them into account when planning and executing a successful study.

    Reducing burdens related to traveling and reimbursement

    DCTs offer the option to minimize the restraints of location or travel logistics when considering trial participation. Patients may be able to avoid or reduce the often long distance travel to clinic sites, which can be viewed as burdensome and disruptive or even unacceptable. This is crucial because clinical sites are often centrally located typically in larger metropolitan areas, whereas patients with rare diseases are spread around the world and often in remote and rural, and even ultra-rural, areas. Technological advances harnessed by a DCT strategy can supplement and virtually replace traditional techniques utilized in studies, making the trials highly flexible and accessible to patients globally, even from the comfort of their own homes.

    In addition to a patient’s own care, travel arrangements may be complicated if there are other family members, especially children (or even aging parents), who require their care. This may necessitate arranging additional care options, such as childcare; if it is the caregiver’s professional full-time job, they may also be required to organize alternative caregivers to take their own place for that time.

    Another considerable burden is that family caregivers may require time off from their own jobs, resulting in potential salary reductions or using precious paid time off. Even if the travel costs are later reimbursed, sometimes patients and families may not have the resources to cover the costs in advance, making participation an even greater challenge.

    Providing monetary support to cover daily expenses while traveling to the site for a study visit, organizing travel arrangements and accommodations, and helping solve for gaps in the care of dependents are crucial to lessen the burden on patients and loved ones, encouraging their participation in rare disease trials, increasing enrollment figures, and improving retention rates.

    Taking patient choice into account by design

    Challenges related to location, availability, and reimbursement directly correlate to how feasible it is for a patient to participate in a study. Traditionally, study designs induce limits and inadvertently cause a significant percentage of key patients to be excluded from the trial pool due to their inability to participate simply because of the trial design.

    Although it can be challenging for sponsors to plan a trial taking the ranges of symptoms and factors into account, designing an inclusive trial increases the patient recruitment rate, which is often lower than desirable. Having a larger and more diverse enrollment ensures that the study population is not inadvertently skewed towards one segment such as mildly-symptomatic patients – a crucial factor in the success of clinical studies and their reliability for treatment development.

    Decentralized trial designs enable improved consideration of patient needs (providing flexibility for patient symptoms, locations, caregivers, and financial worries), affording another important advantage. The protocols are more agile and can be tailored to satisfy a patient’s circumstances to a more customized degree.

    For example, many patients are likely to have a dedicated healthcare team, and even a standard of care (SOC) provider with whom they have been working closely, often having a history that goes back many years. If they can remain with their familiar physician as part of the trial design, trust in the process and long-term retention are enhanced throughout the inevitable ups and downs of trial participation.

    Conclusion

    Decentralized trials and a growing orientation to patient centricity, afford all participants better reasons and easier access to join rare disease trials. DCT designs help overcome challenges related to geography, travel, accommodations, specialized individual patient arrangements, symptom management, expenses, and changing care providers. When these challenges are recognized and addressed to the greatest degree possible, more patients with rare diseases are able to participate in trials and generate more diverse and accurate patient population representation. In return, more sample diversity will provide more conclusive study results, leading to better treatment protocols for all current and future patients of rare diseases.

    Click here to learn about Precision’s approach to decentralized clinical trials >

     

    About the author

    Esther Mahillo is the Vice President of Operational Strategy and Feasibility at Precision For Medicine. Dr. Mahillo earned a PhD in Biochemistry at Autonoma University of Madrid and has 25+ years of experience in the clinical research arena, (22 of them in global oncology trials). Dr. Mahillo is a master’s program professor at 3 different universities and authored 3 books, 21 scientific articles, and 24 contributions to scientific congresses. In 2015, Dr. Mahillo was awarded the first prize of the Spanish Society of Medical Oncology (SEOM) contest for her work on promotion of clinical research.

    References:

    1. Sburlan EA, Voinea LM, Alexandrescu C, et al. Rare ophthalmology diseases. Rom J Ophthalmol. 2019;63(1):10-14.

    2. Wakap SN, Lambert DM, Alry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database [published online September 16, 2019]. Eur J Hum Genet. doi: 10.1038/s41431-019-0508-0.

     

    Precision for Medicine is part of the Precision Medicine Group, an integrated team of experts that extends Precision for Medicine’s therapeutic development capabilities beyond approval and into launch strategies, marketing communication, and payer insights. As one company, the Precision Medicine Group helps pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

    Visit the website
    Clinical Trial Services
    • Overview
    • Global Clinical Trial Support
    • Clinical Trial Management
    • Clinical Development Strategy
    • Clinical Trial Design
    • Biostatistics
    • Clinical Sample Management
    • Clinical Research Organization
    Specialty Lab Services
    • Overview
    • Immune Monitoring
    • Flow Cytometry
    • Genomics
    • Tissue & Liquid Biopsy
    • Bioanalytical Testing
    • Cytokine Analysis
    • Biospecimens
    • Sample Processing
    • Global Specimen Transport & Biostorage
    • Contract Research Organization
    • Bioanalysis
    • Neutralizing Antibody (NAb) Assays
    • PBMC Processing
    Data Sciences
    • Overview
    • Biostatistics
    • Clinical Data Management
    • Biometrics
    • QuartzBio
    • Virtual Sample Inventory Management
    Therapeutic Expertise
    • Overview
    • Preclinical Development
    • Early Phase Trials (I-IIa)
    • Late Phase Trials (IIb-III)
    • Oncology and Immuno-Oncology
    • Rare & Orphan Disease
    • Cell & Gene Therapy
    • Neurology
    • COVID-19
    • Autoimmune & Allergy
    • Pediatric
    • Companion Diagnostics
    About Us
    • Our Passion
    • Meet Our People
    • Careers
    • ESG Policy
    • Regulatory Information

    News & Insights
    • Publications
    • Case Studies
    • Thought Leadership
    • News
    • Events
    © 2023 Precision Medicine Group, LLC. All rights reserved. Privacy Policy    GDPR